Immutep (IMMP) said Monday that a phase 2b trial evaluating eftilagimod alfa in combination with Merck's (MRK) Keytruda to treat head and neck squamous cell cancer produced an "excellent" median overall survival result of 17.6 months.
The firm said the result "compares favorably" with to historical results from the two current standard-of-care approaches, while the drug combination was well-tolerated with no new safety signals.
Immutep said it has requested a meeting with the US Food and Drug Administration to discuss next steps including potential paths to approval.
Immutep shares rose nearly 13% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.